PTGS2 and urinary bladder carcinoma: In bladder carcinomas, a recent Phase 3 clinical trial combining gemcitabine-based chemotherapy regimen with immune checkpoint blockade failed to meet the expected clinical endpoint63, underscoring the clinical pertinence to evaluate COX-2/PGE2 blockade as an adjuvant therapy to enhance chemoimmunotherapeutic efficacy.